• US
  • Ashburn, US

Septic Shock Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

Septic Shock Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
Septic Shock Pipeline Insights
DelveInsight’s ‘Septic Shock Pipeline Insight 2023’ report provides comprehensive global coverage of available, marketed, and pipeline Septic Shock therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Septic Shock pipeline domain.

United States, Nevada, Las Vegas, DelveInsight’s Septic Shock Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Septic Shock therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Septic Shock pipeline domain.

Key Takeaways from the Septic Shock Pipeline Report

  • Over 10+ Septic Shock pipeline therapies are in various stages of development, and their anticipated acceptance in the Septic Shock market would significantly increase market revenue. 
  • Leading Septic Shock companies developing novel drug candidates to improve the Septic Shock treatment landscape include Adrenomed, Inotrem, and others.
  • Promising Septic Shock pipeline therapies in various stages of development include Adrecizumab, Nangibotide, and others.

Septic Shock Overview

Sepsis syndromes span a clinical continuum with variable prognoses. Septic shock, the most severe complication of sepsis, carries a high mortality. Septic shock occurs in response to an inciting agent, which causes both pro-inflammatory and anti-inflammatory immune system activation. This occurs in concert with the activation of monocytes, macrophages, and neutrophils that interact with the endothelium through pathogen recognition receptors and lead to further involvement of cytokines, proteases, kinins, reactive oxygen species, and nitric oxide. As the primary site of this response, the endothelium not only suffers microvascular injury but also activates the coagulation and complement cascades, further exacerbating the vascular injury, leading to capillary leakage. This cascade of events is responsible for sepsis’s clinical signs and symptoms and progression from sepsis to septic shock. Striking a balance between pro-inflammatory responses, which help eradicate the invading microorganism, and anti-inflammatory signals, which keep the inflammatory cascade in check, ultimately determines the degree of morbidity and/or mortality of patients with sepsis. Judicious and early antimicrobial administration, sepsis care bundle use, and early goal-directed therapies have significantly and positively impacted sepsis-related mortality. However, early identification remains the best therapeutic tool for sepsis treatment and management. This activity describes the evaluation and management of septic shock and highlights the role of the interprofessional team in enhancing care delivery for affected patients.

Septic Shock Pipeline Analysis: Drug Profile

Adrecizumab: Adrenomed

Adrecizumab is a proprietary humanized monoclonal adrenomedullin (ADM) specific antibody. This targeted therapy inhibits excessive circulating sepsis-induced ADM, stimulates protective effects on the endothelial barrier, and decreases interstitial vasodilatory effects. Currently, it is in Phase II stage of clinical trial evaluation to treat septic shock.

Discover more about the emerging Septic Shock drugs @ Septic Shock Treatment Drugs

Septic Shock Key Companies

  • Adrenomed
  • Inotrem

Septic Shock Pipeline Therapies

  • Adrecizumab
  • Nangibotide

Septic Shock Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Septic Shock Pipeline Report 

  • Coverage: Global 
  • Key Septic Shock Companies: Adrenomed, Inotrem, and others
  • Key Septic Shock Pipeline Therapies: Adrecizumab, Nangibotide, and others

Find out more about the Septic Shock treatment options in development @ Septic Shock Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Request for a sample report to know more about the leading companies in the septic shock pipeline domain.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/